Protein Z-dependent regulation of coagulation

Thrombosis and Haemostasis

Volumn 86, Issue 1, 2001, Pages 8-13

  Broze G J , Jr ^a  

^a BARNES JEWISH HOSPITAL   (United States)

Author keywords

Factor Xa; Factor XIa; Proteinase inhibitor; Serpin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 11A; BLOOD CLOTTING FACTOR 5 LEIDEN; CALCIUM ION; COMPLEMENTARY DNA; FATTY ACID BINDING PROTEIN; KAOLIN; PHOSPHOLIPID; PLASMA PROTEIN; PROTEINASE INHIBITOR; PROTHROMBIN; RESERPINE; THROMBIN; THROMBOMODULIN; TYROSINE; VITAMIN K GROUP;

BLEEDING DISORDER; BLOOD CLOTTING; BLOOD CLOTTING TEST; CIRCULATION; COMPLEX FORMATION; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE SEVERITY; DISSOCIATION; HUMAN; METABOLIC REGULATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN DEFICIENCY; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; PROTEIN SYNTHESIS INHIBITION; PROTEIN Z DEFICIENCY; THROMBIN TIME; THROMBOSIS; WESTERN BLOTTING;

EID: 0034923318     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1616195     Document Type: Conference Paper

References (47)

1. The isolation of a new warfarin-sensitive protein from bovine plasma
2. Human protein Z
3. The gene for human protein Z is localized to chromosome 13 at band q34 and is coded by eight regular exons and one alternative exon
4. Primary structure of vitamin K-dependent human protein Z
5. Amino acid sequence of human protein Z, a vitamin K-dependent plasma glycoprotein
6. Human plasma protein Z antigen: Range in normal subjects and effect of warfarin therapy
7. Protein Z is a negatively responding acute phase protein
8. Plasma protein Z levels inversely correlate with plasma interleukin-6 in patients with acute leukemia and non-Hodgkin's lymphoma
9. Plasma protein Z levels in healthy newborn infants
10. Protein Z
11. Behavior of plasma protein Z levels in patients with abnormal haemostasis: Correlation with coagulation screening times
12. Protein Z, a new haemostatic factor, in liver disease
13. Plasma protein Z levels in patients with systemic AL amyloidosis
14. Protein Z levels in haemodialysis patients
15. Circulating protein Z in reactive and clonal thrombocytosis and in ITP
16. Localisation of protein Z in vascular lesions of patients with atherosclerosis
17. Comparison of naturally occurring vitamin K-dependent proteins: Correlation of amino acid sequences and membrane binding properties suggests a membrane contact site
18. Interaction of vitamin K-dependent protein Z with thrombin
19. Interaction of human protein Z with thrombin: Evaluation of the species difference in the interaction between bovine and human protein Z and thrombin
20. A characteristic property of vitamin K-dependent plasma protein Z
21. Protein Z deficiency: A new cause of bleeding tendency
22. Protein Z in healthy human individuals and in patients with a bleeding tendency
23. Bleeding tendency of unknown origin and protein Z levels
24. Prothrombotic phenotype of protein Z deficiency
25. Isolation of a protein Z-dependent plasma protease inhibitor
26. The protein Z-dependent protease inhibitor is a serpin
27. cDNA cloning of rasp-1, a novel gene encoding a plasma protein associated with liver regeneration
28. Characterization of protein Z-dependent protease inhibitor
29. Properties of antithrombin-thrombin complex formed in the presence and the absence of heparin
30. Fibrinolysis and the contact system: A role for factor XI in the down-regulation of fibrinolysis
31. Protein Z circulates in plasma in a complex with protein Z-dependent protease inhibitor
32. Protein C inhibitor is a potent inhibitor of the thrombin-thrombomodulin complex
33. Alternation of serpin specificity by a protein cofactor: Vitronectin endows plasminogen activator inhibitor 1 with thrombin inhibitory properties
34. On the target specificity of plasminogen activator inhibitor 1: The role of heparin, vitronectin, and the reactive site
35. Kinetics of inactivation of α-thrombin by plasminogen activator inhibitor-1: Comparison of the effects of native and urea-treated forms of vitronectin
36. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1: Conformational changes of the reactive center upon interactions with target proteases, vitronectin and heparin
37. The suicide substrate reaction between plasminogen activator inhibitor 1 and thrombin is regulated by the cofactors vitronectin and heparin
38. The composition of complexes between plasminogen activator inhibitor 1, vitronectin, and either thrombin or tissue-type plasminogen activator
39. Identification of a strain specific modifier gene for thrombosis in factor V Leiden mice
40. Tissue factor pathway inhibitor (TFPI) gene-disruption produces embryonic lethality in mice
41. Inactivation of the gene for anticoagulant protein C causes lethal perinatal consumptive coagulopathy in mice
42. Lethal thrombosis resulting from heterozygous tissue factor pathway inhibitor deficiency in homozygous factor V Leiden mice
43. High frequency of protein Z deficiency in patients with ischemic stroke
44. Hereditary thrombophilia
45. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood
46. Inherited prothrombotic conditions and premature ischemic stroke
47. Protein Z influences prothrombotic phenotype of factor V Leiden in humans